IP Library Granted Patent US 7,172,285
Granted Patent B1
US 7,172,285 · App. 11/164,898 · Granted Feb 6, 2007

Contact lens with high-order compensation for non-axisymmetric structure

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,172,285
App. No.
11/164,898
Granted
Feb 6, 2007
Kind
B1
Abstract

Contact lenses, such as prism ballasted toric lenses, having anterior and posterior surfaces related by way of non-axisymmetric thickness variation can exhibit a third-order aberration, particularly vertical coma. A wavefront modifier, such as an aspheric surface modification, is incorporated into the lenses to at least partially compensate for the wavefront aberration associated with the non-axisymmetric thickness variation. A magnitude of the modifications can be adjusted to set a target value for any remaining wavefront aberration of the lenses based on a population-wide goal.

Claims (58)

1. A method of making a contact lens, comprising the steps of:

forming a contact lens body having anterior and posterior surfaces aligned along an optical axis for producing spherical or cylindrical corrections;

relating the anterior and posterior surfaces by way of a non-axisymmetric thickness variation to incorporate an orienting feature for orienting the contact lens body about the optical axis;

identifying an optical defect associated with the non-axisymmetric thickness variation of the orienting feature; and

fashioning at least one of the anterior and posterior surfaces as a wavefront modifier that at least partially compensates for the optical defect associated with the non-axisymmetric thickness variation.

2. The method of claim 1 in which the step of identifying includes identifying the optical defect as a non-axisymmetric wavefront aberration associated with the thickness variation.

3. The method of claim 2 in which the step of identifying includes identifying coma associated with the thickness variation.

4. The method of claim 3 in which the step of fashioning includes arranging the wavefront modifier to at least partially compensate for the coma associated with the thickness variation.

5. The method of claim 1 in which the step of identifying includes identifying the optical defect as including a third-order wavefront aberration.

6. The method of claim 5 in which the step of fashioning includes arranging the wavefront modifier to at least partially compensate for the third-order wavefront aberration.

7. The method of claim 6 in which the step of fashioning includes incorporating the wavefront modifier in the anterior surface of the contact lens body.

8. The method of claim 1 in which the thickness variation in combination with the spherical or cylindrical corrections produces a plurality of higher-order aberrations, and the steps of identifying and fashioning include identifying the higher-order aberrations as defects and arranging the wavefront modifier to at least partially compensate for the higher-order aberrations.

9. A method of making a contact lens, comprising steps of:

forming a contact lens body having a non-axisymmetric thickness variation for orienting the contact lens body about an optical axis;

identifying an optical aberration associated with the non-axisymmetric thickness variation; and

modifying optical properties of the contact lens body to at least partially compensate for the identified optical aberration associated with the thickness variation.

10. The method of claim 9 in which the step of identifying includes identifying the optical aberration as vertical coma exhibited by transmissions through the lens body along the optical axis.

11. The method of claim 10 in which the step of modifying includes modifying optical properties of the contact lens body to at least partially compensate for the vertical coma associated with the thickness variation.

12. The method of claim 9 in which the step of identifying includes identifying the optical aberration as including a third-order wavefront aberration.

13. The method of claim 12 in which the step of modifying includes modifying optical properties of the contact lens body to at least partially compensate for the third-order wavefront aberration.

14. The method of claim 9 in which the step of forming includes forming anterior and posterior surfaces of the lens body, and the step of modifying includes modifying at least one of the anterior and posterior surfaces to at least partially compensate for the identified optical aberration associated with the thickness variation.

15. The method of claim 9 in which the step of modifying includes incorporating a variation in a refractive index of the lens body to at least partially compensate for the identified optical aberration.

16. The method of claim 15 in which the variation in refractive index is a non-axisymmetrical variation in refractive index.

17. A batch of contact lenses, comprising:

a plurality of lens bodies having anterior and posterior surfaces that are aligned along an optical axis for producing spherical or cylindrical corrections;

the anterior and posterior surfaces being related by way of non-axisymmetric thickness variations for orienting the contact lens bodies about the optical axis; and

wavefront modifiers being incorporated into at least one of the anterior and posterior surfaces of the lens bodies and at least partially compensating for a wavefront aberration associated with the non-axisymmetric thickness variations to a common target value for any remaining wavefront aberration among the lens bodies.

18. The batch of claim 17 in which the wavefront aberration associated with the non-axisymmetric thickness variations includes a third-order wavefront aberration, and the common target value among the lens bodies is a predetermined amount of the third-order wavefront aberration.

19. The batch of claim 18 in which the predetermined amount of the common target value among the lens bodies is a substantially zero amount of the third-order wavefront aberration.

20. The batch of claim 18 in which the common target value among the lens bodies is an amount based on a population study to provide a target compensation for a similar third-order aberration exhibited by the population.

21. The batch of claim 18 in which the wavefront aberration is coma and the common target value is a predetermined amount of coma.

22. The batch of claim 17 in which the wavefront modifiers are incorporated into at least one of the anterior and posterior surfaces as non-axisymmetrical surface forms that at least partially compensate for the wavefront aberration associated with the thickness variation.

23. A plurality of contact lenses, comprising:

a plurality of contact lens bodies each incorporating a structural feature contributing a third-order wavefront aberration to wavefront propagations through the contact lens bodies; and

a wavefront modifier incorporated into each of the contact lens bodies contributing a complementary third-order wavefront aberration such that in combination with the third-order wavefront aberration contributed by the structural feature, any residual third-order wavefront aberration is substantially the same among the lens bodies.

24. The contact lenses of claim 23 in which the structural features incorporated into the lens bodies contribute different amounts of the third-order wavefront aberration, but amounts of the residual third-order wavefront aberration remain substantially the same.

25. The contact lenses of claim 23 in which at least some of the lens bodies exhibit different amounts of optical power but exhibit substantially the same amount of the residual third-order wavefront aberration.

26. The contact lenses of claim 23 in which the residual third-order wavefront aberration is substantially null.

27. The contact lenses of claim 23 in which the wavefront modifiers contribute different amounts of coma.

28. The contact lenses of claim 23 in which the structural features provide for orienting the contact lens bodies on wearers' eyes.

29. The contact lenses of claim 28 in which the lens bodies are prism ballasted for orienting the lens bodies on the wearers' eyes, and the wavefront modifiers at least partially compensate for optical aberrations associated with the prism ballasting.

30. The contact lenses of claim 29 in which the wavefront modifiers contribute non-axisymmetrical aberrations with respect to optical axes of the wearers' eyes.

31. The contact lenses of claim 30 in which the wavefront modifiers compensate for vertical coma associated with the prism ballasting.

32. The contact lenses of claim 29 in which the lens bodies include anterior and posterior surfaces, and the wavefront modifiers are formed in one of the anterior and posterior surfaces.

33. The contact lenses of claim 32 in which the wavefront modifiers are formed in the anterior surfaces.

34. The contact lenses of claim 29 in which the wavefront modifiers contribute a plurality of the higher-order aberrations.

35. The contact lenses of claim 34 in which at least one of the higher-order aberrations contributed by the wavefront modifiers is coma.

36. A set of ophthalmic biomedical optics, comprising:

a plurality of focusing optics having bodies adapted for contact with biological tissue;

a non-axisymmetric structural feature of the focusing optic bodies that influences optical transmissions of the lens bodies;

a wavefront modifier that further influences optical transmissions of the focusing optic bodies; and

the wavefront modifier exhibiting a third-order aberration that makes similar improvements to the imaging performance of the focusing optic bodies.

37. The optics of claim 36 in which the non-axisymmetric structural feature contributes a third-order aberration and the wavefront modifier at least partially compensates for the third-order aberration of the orienting feature.

38. The optics of claim 37 in which the wavefront modifier compensates for a plurality of third or other higher-order aberrations to improve imaging performance.

39. The optics of claim 38 in which the wavefront modifier provides corrections for both coma and spherical aberration.

40. The optics of claim 36 in which the focusing optic bodies include anterior and posterior surfaces and the wavefront modifier is formed in one of the anterior and posterior surfaces.

41. The optics of claim 40 in which the wavefront modifier is formed at least in part as a non-axisymmetrical surface.

42. The optics of claim 36 in which the wavefront modifier is formed at least in part by refractive index variations in the focusing optic bodies.

Assignments (29)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
PATENT SECURITY AGREEMENT Recorded Jul 1, 2025
From: BAUSCH & LOMB INCORPORATED; ALDEN OPTICAL LABORATORIES, INC.; BAUSCH + LOMB IRELAND LIMITED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 071773/0871 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
PATENT SECURITY AGREEMENT Recorded Oct 4, 2023
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 065120/0086 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 048556/0758) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH COMPANIES INC.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0484 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 043251/0932) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061872/0099 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 056811/0814) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061872/0669 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 059121/0001) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061873/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 031156/0508) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 061778/0446 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 034749/0689) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; UNIVERSITY OF ROCHESTER
Reel/Frame 061778/0146 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Mar 26, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC
To: CREDIT SUISSE
Reel/Frame 020733/0765 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2005
From: ALTMANN, GRIFFITH E.; COX, IAN G.; GREEN, TIMOTHY; REINDEL, WILLIAM T.
To: BAUSCH AND LOMB INCORPORATED
Reel/Frame 016875/0620 →